GELFOND RICHARD L 4
4 · IMAX CORP · Filed Apr 10, 2026
Research Summary
AI-generated summary of this filing
IMAX (IMAX) CEO Richard Gelfond Exercises Options, Sells Shares
What Happened Richard L. Gelfond, CEO of IMAX (IMAX), exercised options to convert 135,046 derivative shares into common stock and sold those same 135,046 shares on April 10, 2026. The exercise converted shares at $31.40 per share (cost $4,240,444) and the open-market sale was at $37.82 per share (proceeds $5,106,873), a gross difference of about $866,429 before fees and taxes. The conversion and sale occurred on the same day.
Key Details
- Transaction date: April 10, 2026
- Conversion (C): 135,046 shares @ $31.40 = $4,240,444 (exercise of options)
- Sale (S): 135,046 shares @ $37.82 = $5,106,873 (open-market)
- Shares/holdings after these transactions (per filing): options 1,537,045; restricted share units 231,562; common shares 765,002
- Footnotes: conversion occurred pursuant to a 10b5-1 plan dated Dec 9, 2025; the options were issued in 2016 and expire June 7, 2026, with earlier vesting tranches in 2016
- Filing status: Report filed April 10, 2026 (timely)
Context This was an option exercise followed by an immediate sale of the shares obtained (often called a cashless exercise). The filing shows both the derivative conversion and the subsequent open-market sale; the 10b5-1 plan note indicates the transactions were made under a pre-arranged trading plan rather than ad-hoc trading. Such sales are common for executives realizing gains from vested options and do not by themselves indicate a change in personal view of the company.
Insider Transaction Report
- Conversion
common shares
[F1]2026-04-10$31.40/sh+135,046$4,240,444→ 900,048 total - Sale
common shares
2026-04-10$37.82/sh−135,046$5,106,873→ 765,002 total - Conversion
stock options (to buy)
[F2][F3][F4]2026-04-10$31.40/sh−135,046$4,240,444→ 1,537,045 totalExercise: $31.40Exp: 2026-06-07→ common shares (135,046 underlying)
- 765,002
common shares (opening balance)
Footnotes (4)
- [F1]Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2025.
- [F2]These options were issued in 2016 and are set to expire on June 7, 2026.
- [F3]The stock options became exercisable in three installments: 162,095 on each of June 7, 2016 and September 1, 2016 and 162,094 on December 31, 2016.
- [F4]This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,537,045, 231,562 and 765,002, respectively.